🧾 What This Document Is

This is a Form 8-K, a special report companies must file with the SEC to announce major news that's important for investors. Think of it as an official headline alert. This specific filing has two connected announcements about a leadership change at Avantor.

🏢 What The Company Does

👉 In simple terms, Avantor is a major global supplier to life science and advanced technology industries. They provide essential chemicals, lab supplies, and services that research labs, pharmaceutical companies, and electronics manufacturers need to do their work.

💼 Executive Changes: A Two-Part Story

This filing details a key transition in the leadership of one of Avantor's major business segments.

Part 1: The Transition Plan (April 17, 2026)

The company told Benoit Gourdier, its current Executive Vice President of the Bioscience and Medtech Products segment, that he would be moving to a new internal role. His new job is to help with "segment integration activities." It's expected he will leave the company entirely by December 31, 2026.

👉 Why it matters: This signals a planned, orderly handover, not a sudden departure. It allows for knowledge transfer while the company finds his permanent replacement.

Part 2: The New Hire (April 23, 2026)

Almost immediately, Avantor announced it has hired Ludovic Brellier for the same role. He will become the new Executive Vice President, Bioscience and Medtech Products and Chief Transformation Officer, starting May 1, 2026.

👉 Why it matters: The company moved quickly to fill the gap, showing stability. The added "Chief Transformation Officer" title suggests Brellier is expected to not just manage the segment but actively reshape or improve it.

🔮 What This Signals

This move is about refreshment and strategic focus. Bringing in a new leader with a "transformation" mandate often indicates the company sees an opportunity to improve performance, efficiency, or growth in that segment. The overlap between Gourdier's transition and Brellier's start is designed to ensure a smooth handoff.

📅 Key Dates

• April 17, 2026: Benoit Gourdier informed of transition.
• May 1, 2026: Ludovic Brellier starts.
• December 31, 2026: Expected date for Benoit Gourdier's final departure.

📦 The Exhibit: The Press Release

Attached to this legal filing is the official press release (Exhibit 99) from April 23, 2026, which contained the public announcement of Ludovic Brellier's hiring. The 8-K formalizes that announcement for the SEC.

🧠 The Analogy

Imagine a sports team needing a new head coach. First, they announce the current coach will finish the season in an advisory role (Gourdier's transition). Then, almost right away, they introduce the new coach who will start immediately and is known for rebuilding teams (Brellier as the "Transformation Officer"). It’s a strategy to change direction without losing continuity.

🧩 Final Takeaway

This filing is about a strategic leadership refresh at Avantor. The company is ensuring a smooth handoff in a key business unit while bringing in new, transformation-focused leadership. The quick timeline signals urgency and a clear plan for the future of its Bioscience and Medtech division.